Javed Qaiser, Alam Faouzi, Krishna Sowmya
Wirral University Teaching Hospital, Psychiatry, Clatterbridge Hospital, Bebington, Wirral CH63 4JY, UK.
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.07.2009.2084. Epub 2009 Nov 22.
A 28-year-old woman with a depressive episode developed hyponatraemia (126 mmol/l), in the absence of hypovolaemia, oedema, or diuretic use, 2 weeks after starting treatment with the antidepressant venlafaxine. Full blood count, potassium, urea, creatinine, thyroid function test, liver function test, amylase, serum cortisol, and glucose were all normal. A repeat blood test 3 days later revealed a further reduction in the sodium concentration to 123 mmol/l. The patient did not have any signs or symptoms of physical disorder secondary to hyponatraemia on this occasion. Her serum sodium reached normal values 2 weeks after stopping treatment with venlafaxine. Hyponatraemia secondary to venlafaxine has been reported in the older population but not in young people. We therefore believe this is an important finding.
一名28岁患有抑郁发作的女性在开始使用抗抑郁药文拉法辛治疗2周后出现低钠血症（126 mmol/L），不存在血容量不足、水肿或使用利尿剂的情况。全血细胞计数、钾、尿素、肌酐、甲状腺功能测试、肝功能测试、淀粉酶、血清皮质醇和血糖均正常。3天后再次进行血液检查发现钠浓度进一步降至123 mmol/L。此次患者没有任何因低钠血症继发身体紊乱的体征或症状。停用文拉法辛治疗2周后，她的血清钠恢复到正常水平。文拉法辛继发的低钠血症在老年人群中已有报道，但在年轻人中未见报道。因此，我们认为这是一项重要发现。
